Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth

2026-02-23
Guardant Health (NasdaqGS:GH) agreed to acquire MetaSight Diagnostics, expanding its liquid biopsy capabilities into early cancer and liver fibrosis detection. The company is growing the reach of its Shield colorectal cancer screening test through new partnerships with Quest Diagnostics and PathGroup. Recent updates also include strong revenue growth and new product launches, adding to the company’s broader oncology diagnostics offering. Guardant Health focuses on blood based tests for...

Do Wall Street Analysts Like Quest Diagnostics Stock?

2026-02-18
Quest Diagnostics has outperformed the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

5 Insightful Analyst Questions From Quest’s Q4 Earnings Call

2026-02-17
Quest Diagnostics delivered a Q4 performance that exceeded Wall Street’s revenue and earnings expectations, prompting a positive market reaction. Management attributed this outcome to strong organic growth across physician, hospital, and consumer channels, with advanced diagnostics and recent partnerships like Fresenius Medical Care and Corewell Health contributing significant volume gains. CEO Jim Davis cited the company’s expansion in specialized testing—such as Alzheimer’s and autoimmune diag

Walmart To Lead Group Of 11 Companies Announcing Annual Dividend Increases In Second Half Of February

2026-02-14
Walmart is expected to announce its 53rd consecutive annual dividend increase in late February. Learn more about the dividend increases here.

Dividend Champion, Contender, And Challenger Highlights: Week Of February 15

2026-02-13
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. The monthly compilation can be overwhelming -- read the weekly breakdown here.

A Look At Quest Diagnostics (DGX) Valuation After Strong Results, 2026 Outlook, Buybacks And New Myeloma Test

2026-02-13
Quest Diagnostics (DGX) just paired a strong fourth quarter and full year 2025 with a confident 2026 outlook, a higher dividend, expanded buybacks, and new high value tests such as its myeloma MRD blood assay. See our latest analysis for Quest Diagnostics. The recent earnings beat, higher dividend, expanded buybacks, and new myeloma MRD test have arrived alongside a strong run in the shares, with a 30 day share price return of 14.95% and a 1 year total shareholder return of 24.88%. This...

Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86

2026-02-13
The board of Quest Diagnostics Incorporated ( NYSE:DGX ) has announced that it will be paying its dividend of $0.86 on...

Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $235

2026-02-12
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $210 to $235.

Forecasting The Future: 6 Analyst Projections For Quest Diagnostics

2026-02-11

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

2026-02-11
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.